Anhui Welman Pharmaceutical Co.,Ltd.
As of 18 November 2026, for the company name Anhui Welman Pharmaceutical Co.,Ltd. as recorded, the chemical-drug catalogue lists 15 active records with this name as holder; 9 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
21 acceptance records as first applicant, grouped into 13 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
复方鱼腥草软胶囊 · No verified English name 2 records · Latest accepted 2026/09/28
Supplement · 2
Diphenhydramine Hydrochloride Injection 1 records · Latest accepted 2026/06/25
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601497 | Generic | 2026/06/25 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Aztreonam For Injection 1 records · Latest accepted 2025/07/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550256 | Supplement | 2025/07/12 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Ethyl Iosapentate Capsules 1 records · Latest accepted 2025/05/21
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501837 | Generic | 2025/05/21 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Morinidazole and Sodium Chloride Injection 1 records · Latest accepted 2025/03/05
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500921 | Generic | 2025/03/05 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Vecuronium Bromide For Injection 1 records · Latest accepted 2025/01/01
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450651 | Supplement | 2025/01/01 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Citicoline Sodium Injection 1 records · Latest accepted 2024/09/25
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450490 | Supplement | 2024/09/25 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Ceftazidime And Avibactam Sodium For Injection 1 records · Latest accepted 2024/04/26
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401277 | Generic | 2024/04/26 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Ceftazidime for Injection 3 records · Latest accepted 2024/03/06
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450174 | Supplement | 2024/03/06 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2450173 | Supplement | 2024/03/06 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2450172 | Supplement | 2024/03/06 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Cefoperazone Sodium and Sulbactam Sodium for Injection 2 records · Latest accepted 2024/03/06
Supplement · 2
注射用头孢唑肟钠 · No verified English name 2 records · Latest accepted 2023/12/25
Generic · 2
Cefazolin Sodium for Injection 2 records · Latest accepted 2022/12/31
Supplement · 2
Cefotaxime Sodium For Injection 3 records · Latest accepted 2022/12/30
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2250781 | Supplement | 2022/12/30 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2250780 | Supplement | 2022/12/30 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2250779 | Supplement | 2022/12/30 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Changes in the last 90 days
2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Marketing application approved: 1 applicationAccepted: 1 application
- 2026/11/03Marketing application approved
Morinidazole and Sodium Chloride Injection
CYHS2500921 · 国药准字H20266458
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Date added to this site: 2026/11/06
View source · Table row 33 ↗ - 2026/09/28Accepted
复方鱼腥草软胶囊 · No verified English name
CYZB2604968
Fact date: 2026/09/28 · Date added to this site: 2026/10/22
View source ↗
Under review
4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 复方鱼腥草软胶囊 · No verified English name | CYZB2604968 | Supplement | 2026/09/28 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| Diphenhydramine Hydrochloride Injection | CYHS2601497 | Generic | 2026/06/25 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| 复方鱼腥草软胶囊 · No verified English name | CYZB2501699 | Supplement | 2025/08/07 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| Ethyl Iosapentate Capsules | CYHS2501837 | Generic | 2025/05/21 | Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
Catalogue holder records
15 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Aztreonam For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20073823 | 2026/08/26 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Vecuronium Bromide For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20084539 | 2026/02/25 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Citicoline Sodium Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20055588 | 2025/09/09 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 注射用头孢唑肟钠 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20253914 | 2025/04/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 注射用头孢唑肟钠 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20253913 | 2025/04/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ceftazidime for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20258064 | 2025/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ceftazidime for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20013402 | 2025/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefoperazone Sodium and Sulbactam Sodium for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20258056 | 2025/04/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefoperazone Sodium and Sulbactam Sodium for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20065012 | 2024/12/23 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefazolin Sodium for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H34020097 | 2024/04/03 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefotaxime Sodium For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H34021986 | 2023/12/26 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefotaxime Sodium For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20237184 | 2023/12/26 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Cefotaxime Sodium For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20013369 | 2023/12/26 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ceftazidime And Avibactam Sodium For Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20255448 | 2025/09/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ceftazidime for Injection | Anhui Welman Pharmaceutical Co.,Ltd. | Anhui Welman Pharmaceutical Co.,Ltd. | 国药准字H20013401 | 2025/04/10 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
9 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 维生素K1 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20230000958 | A | 2025/04/30 | CDE ↗ |
| 阿维巴坦钠 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20230000916 | A | 2025/04/01 | CDE ↗ |
| 盐酸苯海拉明 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20210000548 | A | 2023/09/15 | CDE ↗ |
| 维库溴铵 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20190007423 | A | 2023/10/31 | CDE ↗ |
| 环索奈德 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20190007031 | A | 2023/03/24 | CDE ↗ |
| 盐酸丙帕他莫 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20190006335 | A | 2025/12/02 | CDE ↗ |
| 泛酸钠 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20190004577 | A | 2025/04/18 | CDE ↗ |
| 甲磺酸罗哌卡因 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20190003733 | A | 2025/04/18 | CDE ↗ |
| 依达拉奉 · No verified English name | Anhui Welman Pharmaceutical Co.,Ltd. | Y20170000325 | A | 2024/02/28 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
2 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Diprophylline Injection | CYHS2503961 | Generic | 2025/11/14 | Da Wei (Anhui) Pharma Co., Ltd. romanized; Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
| 维生素K滴剂 · No verified English name | CYHS2500817 | Generic | 2025/02/22 | Hefei Ke Da Bio Technology Co., Ltd. romanized; Anhui Welman Pharmaceutical Co.,Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.